Trial Profile

A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-687 for the Treatment of Diabetic Macular Edema (DME)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs THR 687 (Primary)
Indications Diabetic macular oedema
Focus Adverse reactions
Sponsors Oxurion

Most Recent Events

08 Sep 2021 According to an Oxurion media release, data from this study will be presented at the upcoming annual meeting of the European Society of Retina Specialists 2021, by Raj K. Maturi, M.D.
17 Aug 2021 According to an Oxurion media release, topline data from this study published in Ophthalmology Science, the journal of the American Academy of Ophthalmology.
17 Aug 2021 Results presented in an Oxurion media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com